Dr. Bunn Discusses the Need to Study Drug Combinations in Lung Cancer

Paul A. Bunn, Jr., MD
Published: Saturday, Aug 01, 2015

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

The goal of early lung cancer pioneers, Bunn says, was to cure cancer with chemotherapies that shrank the disease. The strategy at the time was to combine drugs in order to get a complete remission that would last.

Today, lung cancer doctors have TKIs that are very specific and elicit high response rates – but they don’t cure anybody, Bunn says. There are many scientifically rational combinations that could be studied, he says, but these trials need to start happening.

SELECTED
LANGUAGE
Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

The goal of early lung cancer pioneers, Bunn says, was to cure cancer with chemotherapies that shrank the disease. The strategy at the time was to combine drugs in order to get a complete remission that would last.

Today, lung cancer doctors have TKIs that are very specific and elicit high response rates – but they don’t cure anybody, Bunn says. There are many scientifically rational combinations that could be studied, he says, but these trials need to start happening.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x